Boston Scientific Corp (BSX)vsBrainsway Ltd (BWAY)
BSX
Boston Scientific Corp
$48.55
-0.55%
HEALTHCARE · Cap: $70.87B
BWAY
Brainsway Ltd
$13.89
-2.66%
HEALTHCARE · Cap: $572.12M
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 36567% more annual revenue ($20.61B vs $56.22M). BSX leads profitability with a 17.3% profit margin vs 15.6%. BSX trades at a lower P/E of 19.9x. BSX earns a higher WallStSmart Score of 76/100 (B+).
BSX
Strong Buy76
out of 100
Grade: B+
BWAY
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.4%
Fair Value
$37.35
Current Price
$48.55
$11.20 premium
Intrinsic value data unavailable for BWAY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 100.0% YoY
Large-cap with strong market position
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 20.6%
Revenue surging 34.6% year-over-year
Earnings expanding 200.0% YoY
Conservative balance sheet, low leverage
Areas to Watch
No major concerns identified
Smaller company, higher risk/reward
Premium valuation, high expectations priced in
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.
Bull Case : BWAY
The strongest argument for BWAY centers on Revenue Growth, EPS Growth, Debt/Equity. Profitability is solid with margins at 15.6% and operating margin at 12.9%. Revenue growth of 34.6% demonstrates continued momentum.
Bear Case : BSX
No major red flags identified for BSX, but monitor valuation.
Bear Case : BWAY
The primary concerns for BWAY are Market Cap, P/E Ratio, Altman Z-Score. A P/E of 64.9x leaves little room for execution misses.
Key Dynamics to Monitor
BSX profiles as a mature stock while BWAY is a growth play — different risk/reward profiles.
BSX carries more volatility with a beta of 0.62 — expect wider price swings.
BWAY is growing revenue faster at 34.6% — sustainability is the question.
BSX generates stronger free cash flow (171M), providing more financial flexibility.
Bottom Line
BSX scores higher overall (76/100 vs 49/100), backed by strong 17.3% margins and 11.6% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Brainsway Ltd
HEALTHCARE · MEDICAL DEVICES · USA
Brainsway Ltd., a commercial-stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. The company is headquartered in Jerusalem, Israel.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?